Phytochemical Modulation of NF-κB Signaling in Pancreatic Ductal Adenocarcinoma: Preclinical Progress and Pharmacological Perspectives
Pharmaceuticals · 17.11.2026 · 19 (11) · 1828
DOI: 10.3390/ph19111828 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 17.11.2026. Verfasst von Suddhasuchi Das und 7 weiteren Autor:innen. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) remains characterized by aggressive progression, extensive stromal remodeling, early metastatic dissemination, and resistance to systemic therapy. Nuclear factor kappa B (NF-κB) integrates oncogenic, inflammatory, survival, angiogenic, and treatment-induced signals and therefore represents a pharmacologically relevant regulatory node in pancreatic cancer. Phytochemicals including curcumin, xanthohumol, parthenolide, dimethylaminoparthenolide, triptolide, resveratrol, emodin, and related compounds have been investigated as modulators of NF-κB activity, although the strength of mechanistic evidence differs substantially among agents. This review evaluates canonical and noncanonical NF-κB biology in pancreatic cancer, interactions with KRAS, PI3K-AKT, STAT3, MAPK, and Nrf2 signaling, and the consequences of NF-κB modulation for apoptosis, epithelial–mesenchymal transition, angiogenesis, tumor microenvironmental communication, and chemotherapy resistance. Particular emphasis is placed on separating direct pharmacodynamic evidence from downstream pathway association and computational prediction. Curcumin and xanthohumol have been evaluated using direct NF-κB measurements linked to defined antitumor phenotypes and in vivo validation, whereas parthenolide and dimethylaminoparthenolide support a mechanistic relationship between NF-κB activity and gemcitabine resistance. Clinical evidence remains limited and is dominated by early phase curcumin studies, which also illustrate major barriers involving bioavailability, tumor exposure, and target engagement. Future development requires exposure–response analysis, cell-type-specific pharmacodynamics, rational combination therapy, validated biomarkers, and formulations or derivatives with improved pharmacokinetic properties. An evidence-based pharmacological framework may clarify which phytochemical NF-κB modulators warrant further translational development and biomarker-guided evaluation in PDAC.
Zitieren
APA
Das, S., Sharangi, A. B., Rahim, M., Khan, N., Siddiqui, S., Saeed, M., Ahmad, K., & Faisal, S. M. (2026). Phytochemical Modulation of NF-κB Signaling in Pancreatic Ductal Adenocarcinoma: Preclinical Progress and Pharmacological Perspectives. Pharmaceuticals, 19(11), 1828. https://doi.org/10.3390/ph19111828
Vancouver
Das S, Sharangi AB, Rahim M, Khan N, Siddiqui S, Saeed M, et al. Phytochemical Modulation of NF-κB Signaling in Pancreatic Ductal Adenocarcinoma: Preclinical Progress and Pharmacological Perspectives. Pharmaceuticals. 2026;19(11):1828. doi:10.3390/ph19111828
BibTeX
@article{Das2026,
author = {Das, Suddhasuchi and Sharangi, Amit Baran and Rahim, Moniba and Khan, Nida and Siddiqui, Samra and Saeed, Mohd and Ahmad, Khurshid and Faisal, Syed M.},
title = {Phytochemical Modulation of NF-κB Signaling in Pancreatic Ductal Adenocarcinoma: Preclinical Progress and Pharmacological Perspectives},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {11},
pages = {1828},
doi = {10.3390/ph19111828}
}
EUVIMED